Article info
PDFOesophagus
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
- Correspondence to Professor H-U Simon, Institute of Pharmacology, University of Bern, Friedbuehlstrasse 49, CH-3010 Bern, Switzerland; hus{at}pki.unibe.ch
Citation
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
Publication history
- Revised July 13, 2009
- Accepted July 17, 2009
- First published October 13, 2009.
Online issue publication
December 19, 2016
Web only data
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
BMJ Publishing Group Ltd and British Society of Gastroenterology. All rights reserved.